Abstract
Next Generation Sequencing (NGS), together with our evolving knowledge of genes and disease, is likely to change the current practice of medicine and public health by facilitating more accurate, sophisticated, and cost-effective genetic testing. Here, we propose a new molecular approach by using MiSeq Sequencing System (Illumina) to investigate the presence of mutations/variants in genes of JAK/STAT pathway involved in different cytotoxic T lymphocytes (CTL)-mediated immune disorders and to develop and validate new and less expensive molecular protocol based on Next Generation Sequencing.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Leonard WJ, O’Shea JJ (1998) JAKS and STATs: biological implications. Annu Rev Immunol 16:293–322
Ghoreschi K, Laurence A, O’Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273–287
Schumacher RF, Mella P, Badolato R et al (2000) Complete genomic organization of the human JAK3 gene and mutation analysis in severe combined immunodeficiency by single-strand conformation polymorphism. Hum Genet 106:73–79
Pesu M, Candotti F, Husa M et al (2005) JAK3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 203:127–142
Witthuhn BA, Silvennoinen O, Miura O et al (1994) Involvement of the Jak-3 Janus kinase in signaling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370:153–157
Kiyoi H, Yamaji S, Kojima S et al (2007) JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 21:574–576
Cavalcanti E, Gigante M, Mancini V et al (2010) JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients. J Biomed Biotechnol 2010:935764
de Martino M, Gigante M, Cormio L et al (2013) JAK3 in clear cell renal cell carcinoma: mutational screening and clinical implications. Urol Oncol 31(6):930–937
Kolenko V, Wang Q, Riedy MC et al (1997) Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 159:3057–3067
Koskela HL, Eldfors S, Ellonen P et al (2012) Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366(20):1905–1913
TruSeq Custom Amplicon Library Preparation Guide (CATALOG: FC-130-9005DOC)
Acknowledgments
This work was supported in part by grant “Premio di ricerca Gianluca Montel, 2011/2012” from University of Foggia, awarded to Maddalena Gigante and Progetto Strategico Regione Puglia grant (E.R., 2008), Ministero dell’Istruzione, dell’Università e della Ricerca (MiUR) FIRB, CAROMICS grant (E.R., 2011). The authors thank Illumina Fiel Application Scientist for technical support.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Gigante, M., Diella, S., Ranieri, E. (2014). Targeting the JAK/STAT Pathway in Cytotoxic T lymphocytes (CTL) by Next Generation Sequencing (NGS). In: Ranieri, E. (eds) Cytotoxic T-Cells. Methods in Molecular Biology, vol 1186. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1158-5_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1158-5_14
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1157-8
Online ISBN: 978-1-4939-1158-5
eBook Packages: Springer Protocols